- Galcanezumab significantly reduced the number of mean monthly migraine headache days (MHDs) in patients with episodic migraine compared with placebo, according to results of the EVOLVE-2 international randomized phase 3 trial.
- Both once-monthly dosages of 120 and 240 mg were effective, and both resulted in a decrease in use of acute migraine medications.
Why this matters
- These results are similar to a companion phase 3 trial, EVOLVE-1.
- Nearly 70% of people who receive preventive therapy for episodic migraines stop taking the medication within 6 months because of ineffectiveness or intolerability.
- Randomized clinical trial of 915 patients (galcanezumab 120 mg, n=231; 240 mg, n=223; placebo, n=461) with episodic migraine between January 2016 and March 2017.
- Funding: Eli Lilly and Company.
- Mean monthly MHDs were significantly reduced by 2.02 days for galcanezumab 120 mg and 1.90 days for 240 mg vs placebo.
- Significant number of patients in galcanezumab 120 and 240 mg groups experienced ≥50%, ≥75%, and 100% reduction in MHDs vs placebo (P<.001 for all>
- Treatment with both 120 and 240 mg galcanezumab was associated with a significant decrease in the days of use of acute migraine medications.
- Patients with serious medical conditions were excluded.
Coauthored with Anand Ramanathan, PharmD